QGP Short: Increased FDA Enforcement of Drug Advertising Requirements

Send us Fan MailThe FDA is cracking down — hard — on misleading drug advertising across TV, social media, and digital platforms.Why? Too many ads are pushing benefits while burying risks — or skipping fair balance entirely. Influencer campaigns, compounded drug promos, and telehealth ads are under the microscope. As a result, we’ve seen hundreds of warning letters and cease-and-desist letters having already been issued.In this Quality Grind Short, Mike talks about ways to prevent your products from becoming the subject of unfounded claims or non-compliant communication of health benefits and risks.Contact MEDVACON:Message us at @MedvaconLifeSciences on LinkedInVisit our website at www.medvacon.com/contactEmail us at [email protected] for listening! Don't forget to follow us @medvacon on all platforms for updates on blogs and podcasts!